Antimicrobial peptides, nanotechnology, and natural metabolites as novel approaches for cancer treatment.

Abstract:

:Despite the advances in tumor identification and treatment, cancer remains the primary driver of death around the world. Also, regular treatments for the disease are incapable of targeting particular cancer types at different stages since they are not specifically focused on harmful cells since they influence both solid and tumor cells, causing side effects and undesirable symptoms. Therefore, novel strategies should be developed to treat this disease. Several efforts have been made in this direction to find more effective alternatives to cancer treatment, such as the use of antimicrobial peptides (AMPs) with antitumoral activity, nanocarriers and natural compounds from a variety of sources. AMPs are more specific to their targets because of electrostatic interaction between AMPs and the cancer cells' plasma membrane. Nanocarriers may be used for the delivery of non-soluble drugs, which are poorly stable or require a controlled release. In addition, natural compounds have been a rich source of anti-cancer agents for decades. In this review, these three approaches will be discussed, showing recent advances and advantages of using these strategies to treat cancer as well as the combination of these approaches increasing anticancer activity.

journal_name

Pharmacol Ther

authors

Leite ML,da Cunha NB,Costa FF

doi

10.1016/j.pharmthera.2017.10.010

subject

Has Abstract

pub_date

2018-03-01 00:00:00

pages

160-176

eissn

0163-7258

issn

1879-016X

pii

S0163-7258(17)30247-4

journal_volume

183

pub_type

杂志文章,评审
  • Pharmacological targets and emerging treatments for respiratory syncytial virus bronchiolitis.

    abstract::RSV infection of the lower respiratory tract in infants is the leading cause of pediatric hospitalizations and second to malaria in causing infant deaths worldwide. RSV also causes substantial morbidity in immunocompromised and elderly populations. The only available therapeutic is a prophylactic drug called Palivizum...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107712

    authors: Elawar F,Oraby AK,Kieser Q,Jensen LD,Culp T,West FG,Marchant DJ

    更新日期:2020-10-27 00:00:00

  • Allosteric pathways in nuclear receptors - Potential targets for drug design.

    abstract::The nuclear receptor family of transcription factor proteins mediates endocrine function and plays critical roles in the development, physiology and pharmacology. Malfunctioning nuclear receptors are associated with several disease states. The functional activity of nuclear receptors is regulated by small molecular ho...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.10.014

    authors: Fernandez EJ

    更新日期:2018-03-01 00:00:00

  • Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.

    abstract::The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional C...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107587

    authors: Liu T,Luo S,Libby P,Shi GP

    更新日期:2020-09-01 00:00:00

  • Phosphorothioate oligodeoxynucleotides--anti-sense inhibitors of gene expression?

    abstract::Phosphorothioate (PS) oligodeoxynucleotides are relatively nuclease resistant, water soluble analogs of phosphodiester (PO) oligodeoxynucleotides. These molecules are chiral but still hybridize well to their RNA targets. While considered for use as in vivo anti-sense inhibitors of gene expression, their biology, espec...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(91)90032-h

    authors: Stein CA,Tonkinson JL,Yakubov L

    更新日期:1991-12-01 00:00:00

  • Novel pharmacological targets for the rhythm control management of atrial fibrillation.

    abstract::Atrial fibrillation (AF) is a growing clinical problem associated with increased morbidity and mortality. Development of safe and effective pharmacological treatments for AF is one of the greatest unmet medical needs facing our society. In spite of significant progress in non-pharmacological AF treatments (largely due...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.08.002

    authors: Burashnikov A,Antzelevitch C

    更新日期:2011-12-01 00:00:00

  • HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.

    abstract::The human epidermal growth factor receptor (HER) family members are targeted by a growing numbers of small molecules and monoclonal antibodies. Resistance against the epidermal growth factor receptor (EGFR) and HER2-targeting agents is a clinically relevant problem forcing research on optimizing targeting of the HER f...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.01.005

    authors: Kol A,Terwisscha van Scheltinga AG,Timmer-Bosscha H,Lamberts LE,Bensch F,de Vries EG,Schröder CP

    更新日期:2014-07-01 00:00:00

  • The birth of artemisinin.

    abstract::As the first-line antimalarial drugs, artemisinins gained wide acceptance after the emergence of resistance to chloroquine in the 1950s. Artemisinin-based drugs have saved lives, especially in developing countries. The discovery of artemisinin was unique, timely, and fascinating, and the benefits of artemisinin were w...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107658

    authors: Ma N,Zhang Z,Liao F,Jiang T,Tu Y

    更新日期:2020-12-01 00:00:00

  • Progranulin: a growth factor, a novel TNFR ligand and a drug target.

    abstract::Progranulin (PGRN) is abundantly expressed in epithelial cells, immune cells, neurons, and chondrocytes, and reportedly contributes to tumorigenesis. PGRN is a crucial mediator of wound healing and tissue repair. PGRN also functions as a neurotrophic factor and mutations in the PGRN gene resulting in partial loss of t...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.10.003

    authors: Liu CJ,Bosch X

    更新日期:2012-01-01 00:00:00

  • GPCR interacting proteins (GIP).

    abstract::G protein-coupled receptors (GPCR) interact not only with heterotrimeric G proteins but also with accessory proteins called GPCR interacting proteins (GIP). These proteins have important functions. They are implicated in GPCR targeting to specific cellular compartments, in their assembling into large functional comple...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2004.06.004

    authors: Bockaert J,Fagni L,Dumuis A,Marin P

    更新日期:2004-09-01 00:00:00

  • Glutathione metabolism and its role in hepatotoxicity.

    abstract::Glutathione (GSH) fulfills several essential functions: Detoxification of free radicals and toxic oxygen radicals, thiol-disulfide exchange and storage and transfer of cysteine. GSH is present in all mammalian cells, but may be especially important for organs with intense exposure to exogenous toxins such as the liver...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(91)90029-l

    authors: DeLeve LD,Kaplowitz N

    更新日期:1991-12-01 00:00:00

  • The regulation of neuronal gene expression by alcohol.

    abstract::In recent years there has been an explosion of interest in how genes regulate alcohol drinking and contribute to alcoholism. This work has been stimulated by the completion of the human and mouse genome projects and the resulting availability of gene microarrays. Most of this work has been performed in drinking animal...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2009.09.002

    authors: Pignataro L,Varodayan FP,Tannenholz LE,Harrison NL

    更新日期:2009-12-01 00:00:00

  • Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics.

    abstract::Destruction of the established tumour vasculature by a class of compound termed Vascular Disrupting Agents (VDAs) is showing considerable promise as a viable approach for the management of solid tumours. VDAs induce a rapid shutdown and collapse of tumour blood vessels, leading to ischaemia and consequent necrosis of ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.06.001

    authors: Gill JH,Rockley KL,De Santis C,Mohamed AK

    更新日期:2019-10-01 00:00:00

  • The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease.

    abstract::Numerous pro-inflammatory cytokines have been implicated in the pathogenesis of several cardiovascular diseases. Interleukin (IL)-33 is a new member of the IL-1 family of cytokines that promotes Th2 type immune responses by signaling through the ST2L and IL-1RAcP dimeric receptor complex. Furthermore, the biological e...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.02.005

    authors: Miller AM,Liew FY

    更新日期:2011-08-01 00:00:00

  • The role of CB1 in immune modulation by cannabinoids.

    abstract::There is clear evidence that CB(2), historically referred to as the peripheral cannabinoid receptor, mediates many of the immune modulatory effects of cannabinoids. However, cannabinoid receptors cannot be classified simply as central or peripheral since CB(2) has been shown to play a role in the central nervous syste...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2012.12.004

    authors: Kaplan BL

    更新日期:2013-03-01 00:00:00

  • Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity.

    abstract::Cytotoxic drug-induced nausea and vomiting are the side effects most feared by cancer patients. Emesis is an instinctive defense reaction caused by the somatoautonomic nerve reflex, which is integrated in the medulla oblongata. Emesis caused by cytotoxic drugs such as cisplatin is associated with an increase in the co...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(03)00057-3

    authors: Minami M,Endo T,Hirafuji M,Hamaue N,Liu Y,Hiroshige T,Nemoto M,Saito H,Yoshioka M

    更新日期:2003-08-01 00:00:00

  • Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities.

    abstract::Targeted therapies have changed the landscape of treatments for non-small cell lung cancer (NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring genetic alterations in four oncogenes, and agents targeting additional oncogenic drivers are under investigation. Standard first-line chemother...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.08.007

    authors: Yoda S,Dagogo-Jack I,Hata AN

    更新日期:2019-01-01 00:00:00

  • The opioid system in neurologic and psychiatric disorders and in their experimental models.

    abstract::Evidence from experimental and clinical studies suggests the involvement of the endogenous opioid system in several neurologic and psychiatric disorders (Alzheimer's, Huntington's and Parkinson's diseases, drug-induced movement disorders, Gilles de la Tourette syndrome, stroke, ischemia, brain and spinal cord injury, ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(90)90026-x

    authors: Gulya K

    更新日期:1990-01-01 00:00:00

  • VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.

    abstract::Hyperkinetic movement disorders comprise a variety of conditions characterized by involuntary movements, which include but are not limited to tardive dyskinesia, chorea associated with Huntington's Disease, and tic disorders. The class of medications that have been used to treat these conditions includes Vesicular Mon...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107580

    authors: Koch J,Shi WX,Dashtipour K

    更新日期:2020-08-01 00:00:00

  • Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells.

    abstract::In the search for new approaches to cancer therapy, the first alkyllysophospholipid (ALP) analogs were designed and studied about two decades ago, either as potential immunomodulators or as antimetabolites of phospholipid metabolism. In the meantime, it has been demonstrated that they really act in this way. However, ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(95)00001-w

    authors: Brachwitz H,Vollgraf C

    更新日期:1995-04-01 00:00:00

  • The canine model with chronic, complete atrio-ventricular block.

    abstract::Proarrhythmic susceptibility to drug-induced Torsades de Pointes is restricted to individuals with a predisposed phenotype characterized by a reduced repolarization reserve. Additional factors are often involved in a further impairment of repolarization, possibly culminating with dangerous ventricular polymorphic tach...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2008.03.006

    authors: Oros A,Beekman JD,Vos MA

    更新日期:2008-08-01 00:00:00

  • Metabolic polymorphisms.

    abstract::Polymorphisms have been detected in a variety of xenobiotic-metabolizing enzymes at both the phenotypic and genotypic level. In the case of four enzymes, the cytochrome P450 CYP2D6, glutathione S-transferase mu, N-acetyltransferase 2 and serum cholinesterase, the majority of mutations which give rise to a defective ph...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(93)90053-g

    authors: Daly AK,Cholerton S,Gregory W,Idle JR

    更新日期:1993-02-01 00:00:00

  • Oxidative pathways in cardiovascular disease: roles, mechanisms, and therapeutic implications.

    abstract::Despite some recent declines, cardiovascular disease (CVD) remains the major cause of death in the United States and worldwide. Most recent advances in the treatment of CVD states have been produced by inhibition of mechanisms involved in disease progress. Many studies conducted in the last decade have illustrated inc...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(00)00114-5

    authors: Wattanapitayakul SK,Bauer JA

    更新日期:2001-02-01 00:00:00

  • Targeting peroxisome proliferator-activated receptors: A new strategy for the treatment of cardiac fibrosis.

    abstract::Cardiac fibrosis is a pathogenic factor of many cardiovascular diseases (CVD), which seriously affects people's life, and health and causes huge economic losses. Increasing evidence has shown that peroxisome proliferator-activated receptors (PPARs) can regulate the progression of cardiac fibrosis. For the first time, ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107702

    authors: Lu Q,Guo P,Guo J,Ares I,Lopez-Torres B,Martínez-Larrañaga MR,Wang X,Anadón A,Martínez MA

    更新日期:2020-10-04 00:00:00

  • Protein kinase inhibitors and antibiotic resistance.

    abstract::While antibiotics revolutionized the treatment of infectious disease in the 20th century, bacterial resistance now threatens to render many of them ineffective. Aminoglycosides are a class of clinically important antibiotics used in the treatment of infections caused by Gram-positive and -negative organisms. They are ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(02)00197-3

    authors: Burk DL,Berghuis AM

    更新日期:2002-02-01 00:00:00

  • Role of inflammatory chemokines in hypertension.

    abstract::Hypertension is associated with immune cells activation and their migration into the kidney, vasculature, heart and brain. These inflammatory mechanisms are critical for blood pressure regulation and mediate target organ damage, creating unique novel targets for pharmacological modulation. In response to angiotensin I...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107799

    authors: Mikolajczyk TP,Szczepaniak P,Vidler F,Maffia P,Graham GJ,Guzik TJ

    更新日期:2020-12-24 00:00:00

  • KIT as a therapeutic target for non-oncological diseases.

    abstract::KIT is a receptor tyrosine kinase that after binding to its ligand stem cell factor activates signaling cascades linked to biological processes such as proliferation, differentiation, migration and cell survival. Based on studies performed on SCF and/or KIT mutant animals that presented anemia, sterility, and/or pigme...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.12.008

    authors: Martinez-Anton A,Gras D,Bourdin A,Dubreuil P,Chanez P

    更新日期:2019-05-01 00:00:00

  • Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function.

    abstract::This article is a review of cyclic nucleotide phosphodiesterase(s) (CN PDE) from the point of view of the relationships between the newer aspects of the complex enzymology of CN PDE and recent major advances in CN PDE pharmacology. A consolidation of isozyme nomenclature to the proposed family designations is recommen...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(91)90039-o

    authors: Thompson WJ

    更新日期:1991-01-01 00:00:00

  • Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation.

    abstract:UNLABELLED:Preclinical animal models are useful tools to better understand tumor initiation and progression and to predict the activity of an anticancer agent in the clinic. Ideally, these models should recapitulate the biological characteristics of the tumor and of the related tumor microenvironment (e.g. vasculature,...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.01.001

    authors: Wartha K,Herting F,Hasmann M

    更新日期:2014-06-01 00:00:00

  • PARP inhibition in the ovarian cancer patient: Current approvals and future directions.

    abstract::Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the therapeutic management of solid tumors, particularly ovarian cancer. Initially studied in BRCA deficient tumors, the Food and Drug Administration (FDA) indications have expanded to include other homologous recombination deficient tumors as well as bio...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107588

    authors: Kurnit KC,Avila M,Hinchcliff EM,Coleman RL,Westin SN

    更新日期:2020-09-01 00:00:00

  • Atypical behavioural effects of lorazepam: clues to the design of novel therapies?

    abstract::Aside from their pharmacokinetic properties, e.g. their speed of action and the duration of residual effects, benzodiazepines are still considered as equivalent in terms of their effects on cognition. Here we review evidence suggesting that certain benzodiazepines, especially lorazepam, differ in a number of respects,...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2010.01.004

    authors: Giersch A,Boucart M,Elliott M,Vidailhet P

    更新日期:2010-04-01 00:00:00